JP2008543860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008543860A5 JP2008543860A5 JP2008517067A JP2008517067A JP2008543860A5 JP 2008543860 A5 JP2008543860 A5 JP 2008543860A5 JP 2008517067 A JP2008517067 A JP 2008517067A JP 2008517067 A JP2008517067 A JP 2008517067A JP 2008543860 A5 JP2008543860 A5 JP 2008543860A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- propyl
- ethyl
- phenyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- CNMFHDIDIMZHKY-UHFFFAOYSA-N methyl 2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- -1 3- (trifluoromethyl) phenyl Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 0 *C[n]1ncc(-c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C(*)*)c1 Chemical compound *C[n]1ncc(-c2nc(N(*)C(N(*)C3=O)=O)c3[n]2C(*)*)c1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69140805P | 2005-06-16 | 2005-06-16 | |
| US60/691,408 | 2005-06-16 | ||
| PCT/US2006/023167 WO2006138376A1 (en) | 2005-06-16 | 2006-06-14 | Prodrugs of a2b adenosine receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008543860A JP2008543860A (ja) | 2008-12-04 |
| JP2008543860A5 true JP2008543860A5 (enExample) | 2009-06-25 |
| JP5044823B2 JP5044823B2 (ja) | 2012-10-10 |
Family
ID=37215988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517067A Expired - Fee Related JP5044823B2 (ja) | 2005-06-16 | 2006-06-14 | A2bアデノシンレセプターアンタゴニストのプロドラッグ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7625881B2 (enExample) |
| EP (2) | EP2301937A1 (enExample) |
| JP (1) | JP5044823B2 (enExample) |
| KR (1) | KR20080016645A (enExample) |
| CN (1) | CN101198608B (enExample) |
| AU (1) | AU2006259411B2 (enExample) |
| CA (1) | CA2612344A1 (enExample) |
| IL (1) | IL188103A0 (enExample) |
| MX (1) | MX2007015909A (enExample) |
| NO (1) | NO20080278L (enExample) |
| NZ (1) | NZ564326A (enExample) |
| RU (2) | RU2415858C2 (enExample) |
| WO (1) | WO2006138376A1 (enExample) |
| ZA (1) | ZA200710878B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US20080194593A1 (en) * | 2001-11-09 | 2008-08-14 | Rao Kalla | A2b adenosine receptor antagonists |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| DK1658291T3 (da) * | 2003-08-25 | 2013-10-28 | Dogwood Pharmaceuticals Inc | Substituerede 8-heteroaryl xanthiner |
| RU2391103C2 (ru) | 2004-10-15 | 2010-06-10 | Си Ви Терапьютикс, Инк. | Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| CN101198608B (zh) * | 2005-06-16 | 2011-04-27 | 吉利德帕洛阿尔托股份有限公司 | A2b腺苷受体拮抗剂的前药 |
| CA2849661A1 (en) | 2006-03-17 | 2007-09-27 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| JP6106437B2 (ja) | 2010-01-07 | 2017-03-29 | アルカーメス ファーマ アイルランド リミテッド | 複素芳香族化合物のプロドラッグ |
| AU2011271510A1 (en) * | 2010-06-30 | 2013-01-10 | Gilead Sciences, Inc. | Use of A2B adenosine receptor antagonists for treating pulmonary hypertension |
| US8940751B2 (en) | 2010-09-13 | 2015-01-27 | Advinus Therapeutics Private Limited | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
| AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| JP2014514300A (ja) * | 2011-04-08 | 2014-06-19 | スファエラ ファーマ ピーティーイー リミテッド | 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法 |
| CA2875718A1 (en) | 2012-06-08 | 2013-12-12 | Selcia Limited | Macrocyclic inhibitors of flaviviridae viruses |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| NZ724503A (en) | 2012-06-08 | 2017-12-22 | Gilead Sciences Inc | Macrocyclic inhibitors of flaviviridae viruses |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| AU2016372408B2 (en) * | 2015-12-14 | 2021-05-13 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Water-soluble derivatives of 3,5-diphenyl-diazole compounds |
| IL277144B2 (en) * | 2018-03-05 | 2024-06-01 | Teon Therapeutics Inc | Adenosine receptor antagonists and uses thereof |
| JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
| TW202327612A (zh) * | 2021-09-10 | 2023-07-16 | 美商天恩治療有限公司 | 使用腺苷受體拮抗劑之改良療法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| TW252044B (enExample) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6815446B1 (en) * | 1999-08-31 | 2004-11-09 | Vanderbilt University | Selective antagonists of A2B adenosine receptors |
| WO2001060350A2 (en) * | 2000-02-17 | 2001-08-23 | Cv Therapeutics, Inc. | Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
| US6387913B1 (en) | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| ATE520694T1 (de) * | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
| US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US7304070B2 (en) * | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EA007468B1 (ru) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| AU2003223497A1 (en) | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| WO2004074247A2 (en) * | 2003-02-19 | 2004-09-02 | Endacea, Inc. | A1 adenosine receptor antagonists |
| AU2003249604B2 (en) * | 2003-05-06 | 2011-06-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| DK1658291T3 (da) * | 2003-08-25 | 2013-10-28 | Dogwood Pharmaceuticals Inc | Substituerede 8-heteroaryl xanthiner |
| DE602004018808D1 (de) * | 2003-10-31 | 2009-02-12 | Cv Therapeutics Inc | Antagonisten des a2b-adenosinrezeptors |
| SI1789053T1 (sl) * | 2004-09-01 | 2012-09-28 | Gilead Sciences Inc | Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev |
| RU2391103C2 (ru) * | 2004-10-15 | 2010-06-10 | Си Ви Терапьютикс, Инк. | Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b |
| CN101198608B (zh) | 2005-06-16 | 2011-04-27 | 吉利德帕洛阿尔托股份有限公司 | A2b腺苷受体拮抗剂的前药 |
| CA2849661A1 (en) * | 2006-03-17 | 2007-09-27 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| ES2437871T3 (es) * | 2006-07-07 | 2014-01-14 | Gilead Sciences, Inc. | Moduladores del receptor tipo toll 7 |
| BRPI0909157A2 (pt) * | 2008-03-26 | 2015-11-24 | Advinus Therapeutics Private Ltd | compostos heterocíclicos como antagonistas de receptores de adenosina |
-
2006
- 2006-06-14 CN CN2006800213389A patent/CN101198608B/zh not_active Expired - Fee Related
- 2006-06-14 EP EP10011665A patent/EP2301937A1/en not_active Withdrawn
- 2006-06-14 WO PCT/US2006/023167 patent/WO2006138376A1/en not_active Ceased
- 2006-06-14 NZ NZ564326A patent/NZ564326A/en not_active IP Right Cessation
- 2006-06-14 KR KR1020077029351A patent/KR20080016645A/ko not_active Ceased
- 2006-06-14 US US11/453,414 patent/US7625881B2/en active Active
- 2006-06-14 AU AU2006259411A patent/AU2006259411B2/en not_active Ceased
- 2006-06-14 JP JP2008517067A patent/JP5044823B2/ja not_active Expired - Fee Related
- 2006-06-14 EP EP06773161A patent/EP1891070A1/en not_active Withdrawn
- 2006-06-14 CA CA002612344A patent/CA2612344A1/en not_active Abandoned
- 2006-06-14 MX MX2007015909A patent/MX2007015909A/es active IP Right Grant
- 2006-06-14 RU RU2007146669/04A patent/RU2415858C2/ru not_active IP Right Cessation
-
2007
- 2007-12-13 IL IL188103A patent/IL188103A0/en unknown
- 2007-12-14 ZA ZA200710878A patent/ZA200710878B/xx unknown
-
2008
- 2008-01-15 NO NO20080278A patent/NO20080278L/no not_active Application Discontinuation
-
2009
- 2009-11-13 US US12/618,390 patent/US20100056538A1/en not_active Abandoned
-
2010
- 2010-12-09 RU RU2010150615/04A patent/RU2010150615A/ru not_active Application Discontinuation
-
2011
- 2011-01-21 US US13/011,446 patent/US8143249B2/en not_active Expired - Fee Related